Background The management of metastatic breast cancer requires monitoring of the tumor
burden to determine the response to treatment, and improved biomarkers are needed. …

Cancers acquire resistance to systemic treatment as a result of clonal evolution and
selection 1 , 2 . Repeat biopsies to study genomic evolution as a result of therapy are difficult, …

Plasma of cancer patients contains cell-free tumor DNA that carries information on tumor
mutations and tumor burden. Individual mutations have been probed using allele-specific …

Existing methods to improve detection of circulating tumor DNA (ctDNA) have focused on
genomic alterations but have rarely considered the biological properties of plasma cell-free …

Circulating tumour DNA analysis can be used to track tumour burden and analyse cancer
genomes non-invasively but the extent to which it represents metastatic heterogeneity is …

Background The major clinical challenge in the treatment of high-grade serous ovarian cancer
(HGSOC) is the development of progressive resistance to platinum-based chemotherapy. …

Inhibition of the chemokine receptor CXCR4 in combination with blockade of the PD-1/PD-L1
T cell checkpoint induces T cell infiltration and anticancer responses in murine and human …

Background Circulating tumour DNA (ctDNA) carrying tumour-specific sequence alterations
may provide a minimally invasive means to dynamically assess tumour burden and …

Circulating tumor-derived DNA (ctDNA) can be used to monitor cancer dynamics noninvasively.
Detection of ctDNA can be challenging in patients with low-volume or residual disease, …

Introduction Detection and monitoring of circulating tumor DNA (ctDNA) is rapidly becoming
a diagnostic, prognostic and predictive tool in cancer patient care. A growing number of …